Blade Therapeutics expands anti-fibrotic pipeline with acquisition of ATXCo and its autotaxin inhibitor
“With the addition of this IND enabled program to our pipeline, we advance our agenda to bring innovative treatments to patients with fibrotic disorders,” stated Wendye Robbins, M.D.,